{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"MLN8237"},{"type":"CodeName","name":"MLN 8237"},{"type":"Synonym","name":"Aurora A kinase inhibitor MLN8237"},{"type":"ChemicalStructureName","name":"benzoic acid, 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxy-"},{"type":"CASRegistryName","name":"1028486-01-2"},{"type":"CodeName","name":"MLN-8237"}],"definition":{"html":"A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","text":"A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C71717","nciConceptName":"Alisertib","termId":561286,"name":"alisertib","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"alisertib"},{"aliases":[{"type":"CASRegistryName","name":"1208255-63-3"},{"type":"Synonym","name":"MLN8237 sodium"},{"type":"Synonym","name":"MLN8237-004"}],"definition":{"html":"The sodium salt form of alisertib, a second-generation, orally bioavailable, selective inhibitor of the serine/threonine protein kinase Aurora A kinase, with potential antineoplastic activity. Upon oral administration, alisertib targets, binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation in susceptible cancer cells. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers and plays a key role in cancer cell proliferation.","text":"The sodium salt form of alisertib, a second-generation, orally bioavailable, selective inhibitor of the serine/threonine protein kinase Aurora A kinase, with potential antineoplastic activity. Upon oral administration, alisertib targets, binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation in susceptible cancer cells. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers and plays a key role in cancer cell proliferation."},"drugInfoSummaryLink":null,"nciConceptId":"C142912","nciConceptName":"Alisertib Sodium","termId":810689,"name":"alisertib sodium","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"alisertib-sodium"}],"links":null}